Aggression in Children Unraveling gene environment interplay to inform Treatmen...
Aggression in Children Unraveling gene environment interplay to inform Treatment and InterventiON strateg
Aggression inflicts a huge personal, psychological and financial burden on affected individuals, their relatives, and society at large. Despite large scientific, preventive, and treatment investments, no decrease in aggressive beh...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto ACTION
Líder del proyecto
STICHTING VU
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
9M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Aggression inflicts a huge personal, psychological and financial burden on affected individuals, their relatives, and society at large. Despite large scientific, preventive, and treatment investments, no decrease in aggressive behavior is seen. This calls for a shift to new approaches. By capitalising on comprehensive longitudinal cohorts, recent advances in genetic, biological, epidemiological, and clinical fields, and combining such interdisciplinary expertise the ACTION consortium will dissect the etiology and pathogenesis of aggression. Based on new insights, ACTION will inform the development of novel diagnostic tools and causative targets and guide the development of treatment and prevention strategies. ACTION is built on interrelated work packages with a focus on a) clinical epidemiology and current classification and treatment problems; b) genetic epidemiology, including Genome Wide Association studies and epigenetics; c) gene-environment correlation and interaction; d) biomarkers and metabolomics. ACTION will deliver an overarching framework that combines a thorough understanding of pathways leading to aggression with a map of current gaps, best practices on clinical, ethical, legal, and social issues. Based on this framework, ACTION will develop novel biomarkers suitable for large-scale applications in children and combine biomarker data with new insights into the effects of gender, age, and comorbidity. ACTION will provide guidance in optimising current intervention programs and deliver new biological targets to pave the way for novel therapeutic interventions. ACTION will provide a decision tree to guide personalised intervention programmes and will have direct and sustained impact on reducing paediatric aggression. Its overarching aim is to reduce aggression by developing approaches that take individual differences in genetic and environmental susceptibility into account, thereby leading to better understanding of personalised intervention programs.